Nature selects Temprian Therapeutics as a finalist for their Spinoff Prize 2020.
The startup belongs to the top 12 science-based companies to have emerged from academic labs worldwide over the past three years.
Temprian Therapeutics is working hard to launch a drug for the treatment of vitiligo!
Between 35 and 70 million people suffer from vitiligo worldwide. This depigmentation disease causes a lot of hardship for the patients. People use a variety of strategies ranging between makeup, bleaching, skin transplants, corticosteroids and UV therapy to manage their disease. Remedies are few and far between. Only a person suffering from vitiligo can truly understand the stress the disease brings to daily life. Scientific research has however shed some light on the disease. While patients have a genetic predisposition for vitiligo, stress is the ultimate trigger for progressive loss of skin color. Temprian Therapeutics is developing a new way to treat vitiligo by injecting DNA coding for a modified heat shock protein HSP70i to stop the autoimmune response at the outset. We are now looking for investments and donations to get clinical trials off the ground.
